BioCentury | Jun 15, 2018
Clinical News

Eureka reports Phase I response data for anti-CD19 T cell therapy in lymphoma

Eureka Therapeutics Inc. (Emeryville, Calif.) reported preliminary data from 17 evaluable patients with CD19-positive, relapsed and refractory B cell lymphoma in a Phase I trial showing that IV ET190L1-ARTEMIS led to seven complete metabolic responses...
BioCentury | Jan 26, 2018
Financial News

Eureka raises $60M series D

Cancer company Eureka Therapeutics Inc. (Emeryville, Calif.) raised $60 million on Jan. 22 in a series D round led by existing investor Acorn Pacific Ventures. New investor GP Capital also participated, as did all existing...
BioCentury | Jan 22, 2018
Financial News

Eureka raises $60M series D

...series C round led by Yuan Capital (see BioCentury Extra, Feb. 23, 2014) . Elizabeth S. Eaton ET190 Eureka...
Items per page:
1 - 3 of 3